MARKET

CALA

CALA

Calithera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.26
-0.04
-0.75%
Closed 16:00 07/08 EDT
OPEN
5.33
PREV CLOSE
5.30
HIGH
5.33
LOW
5.19
VOLUME
333.55K
TURNOVER
--
52 WEEK HIGH
8.18
52 WEEK LOW
2.450
MARKET CAP
370.54M
P/E (TTM)
-3.0319
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CALA stock price target is 11.50 with a high estimate of 20.00 and a low estimate of 9.00.

EPS

CALA News

More
Hedge Funds Are Selling Calithera Biosciences Inc (CALA)
Insider Monkey · 2d ago
Cramer Advises His Viewers On Micron, Marvell And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Micron Technology, Inc. (NASDAQ: MU) shouldn't have been down on Wednesday.
Benzinga · 6d ago
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 6d ago
Cramer's lightning round: BlackRock is a buy
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 07/01 23:39
Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/04 20:22
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/02 12:00
Calithera Biosciences To Present Telaglenastat KEAPSAKE Trial In Progress Poster At ASCO
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today
Benzinga · 05/29 12:37
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting
The KEAPSAKE study (NCT04265534) will explore telaglenastat versus placebo in combination with a standard-of-care regimen of immunotherapy and chemotherapy as first-line treatment for patients with non-small cell lung cancers (NSCLC) with KEAP1/NRF2 mutations.
GlobeNewswire · 05/29 12:00

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About CALA

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
More

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.